Rosch Elmer Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 10-01-2025
- Paid Up Capital ₹ 0.10 M
as on 10-01-2025
- Company Age 13 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Revenue -99.50%
(FY 2020)
- Profit -190.71%
(FY 2020)
- Ebitda 90.34%
(FY 2020)
- Net Worth -2.61%
(FY 2020)
- Total Assets -48.47%
(FY 2020)
About Rosch Elmer Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Pooja Pandita and Raghav Mittal serve as directors at the Company.
- CIN/LLPIN
U24232CH2011PTC032910
- Company No.
032910
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
29 Apr 2011
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- Location
Chandigarh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Rosch Elmer Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pooja Pandita  | Director | 26-Mar-2015 | Current |
| Raghav Mittal | Director | 16-Oct-2021 | Current |
Financial Performance of Rosch Elmer Pharmaceuticals.
Rosch Elmer Pharmaceuticals Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 99.5% decrease. The company also saw a substantial fall in profitability, with a 190.71% decrease in profit. The company's net worth dipped by a decrease of 2.61%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Rosch Elmer Pharmaceuticals?
In 2017, Rosch Elmer Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Maxport India Private LimitedActive 11 years 2 monthsPooja Pandita and Raghav Mittal are mutual person
- Interphar Healthcare Private LimitedActive 15 years 11 months
Pooja Pandita and Raghav Mittal are mutual person
- Searle Labs Private LimitedActive 15 years 11 months
Pooja Pandita and Raghav Mittal are mutual person
- Arvat Health Ventures Private LimitedActive 25 years 6 months
Pooja Pandita and Raghav Mittal are mutual person
- Swizinger Health Care Private LimitedActive 16 years 4 months
Pooja Pandita and Raghav Mittal are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Rosch Elmer Pharmaceuticals?
Unlock and access historical data on people associated with Rosch Elmer Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Rosch Elmer Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Rosch Elmer Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
